Syngene International Limited — PPTs, 23-01-2025: Investor Presentation

**Financial Highlights:**

Syngene International reported Q3 FY25 revenue from operations of Rs 944 Cr, reflecting a growth of 11% year-over-year. The operating EBITDA margin improved to 30%, up from 27% in Q3 FY24, with profit after tax (PAT) before exceptional items at Rs 131 Cr, an increase of 14% YoY. For the nine months of FY25, revenues totaled Rs 2,624 Cr, showing a 2% YoY increase, while PAT before exceptional items decreased by 12% to Rs 292 Cr.

**Strategic Initiatives and Growth Drivers:**

The company is witnessing strong growth in its Research Services and Contract Development and Manufacturing Organization (CDMO) segments, particularly in biologics, which signals a positive trend for future contracts and revenue generation. The conversion of pilot projects into full-fledged contracts demonstrates growing client confidence in Syngene's capabilities.

**Business Developments:**

Syngene continues to establish collaborations that expand its operational capabilities, such as repeat orders from existing customers and new integrated project collaborations encompassing drug development to clinical manufacturing.

**Market Position and Competitive Advantage:**

With a strong client base comprising 14 of the top 20 global pharmaceutical companies and over 400 active clients, Syngene's robust infrastructure and innovative service offerings maintain its competitive edge in the biotech and pharmaceuticals industries.

**Investor Implications:**

The sustained revenue growth and enhanced profit margins signal a positive outlook for Syngene, making it an attractive option for investors looking for exposure in the biotech sector, especially given its integrated approach across various phases of drug development and manufacturing.